The latest cannabis health, science and regulatory news from the UK and Europe.
Interest in medical cannabis for autism is growing among patients, families and clinicians, but research has yet to establish whether it is an effective treatment.
Experts will examine the impact of Germany’s cannabis reforms on patient care, prescribing and access to treatment.
‘Without a clear policy, employers are more likely to be influenced by their understanding of recreational drug use.’
Findings point to differences in risk perception, communication and confidence discussing cannabis in cancer care.
Devon Partnership NHS Trust has approved procedures for patients to continue taking their prescribed cannabis-based medications while in hospital.
The study is evaluating MRX1, the company’s proprietary CBD-based oral solution, as a treatment for chemotherapy-induced peripheral neuropathy (CIPN).
The CBD manufacturer has received a draft positive scientific opinion from EFSA on its Novel Food application.
Germany has voted to ban medical cannabis flower from its statutory health insurance scheme.
Europe’s dedicated medical cannabis education series for clinicians and industry professionals announces two autumn events — 4 November at Mainhaus, Frankfurt, and 26 November at Conway Hall, London
France’s incoming generalised medical cannabis framework has edged closer to clearing its last remaining hurdle.
Pharmacist independent prescribers accounted for 61.9% of the total items prescribed between January 2019 and May 2025.
UK imports of the medical cannabis and the range of products available to patients both doubled in 2025.
France’s medical cannabis experiment showed treatment was effective in reducing opioid use across four indications.
Upcoming Symposiums
Evidence-led education for clinicians, industry and patient advocates — across Europe.
Every ticket includes 12 months’ free MCCS membership — worth up to £120.
See all events4 November 2026
Frankfurt · Mainhaus
26 November 2026
London · Conway Hall
